Clearmind Medicine Inc
Research Clearmind Medicine Inc (CMND) on Bullrun: market cap USD 14.12M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCMND
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 14.12M
- Financial periodQ3 2026
- RevenueUSD 0
- Net income-USD 907.29K
- Free cash flow-USD 2.71M
Valuation Snapshot
latest market cap is USD 14.12M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 3.86M | -USD 4.73M | n/a | -303.5 | USD 3.92M | USD 1.78M | USD 1.19M |
| FY2024 | USD 0 | -USD 5.25M | -USD 4.86M | n/a | -678 | USD 6.57M | USD 53.14K | USD 3.11M |
| FY2023 | USD 0 | -USD 8.62M | -USD 6.30M | n/a | -5679.08 | USD 5.43M | USD 0 | USD 983.47K |
| FY2022 | USD 0 | -USD 6.89M | -USD 3.73M | n/a | -63440.2 | USD 128.78K | USD 38.39K | -USD 1.11M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 14.12M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.71M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.05M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.75M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 7.96M | n/a | n/a | n/a |
About Clearmind Medicine Inc
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Clearmind Medicine Inc's market cap?
Clearmind Medicine Inc's market capitalization is USD 14.12M.
What does Clearmind Medicine Inc do?
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression.